ArticleOpen medicine (Warsaw, Poland)2025
Development of a nomogram for predicting cancer-specific survival in patients with renal pelvic cancer following surgery.
Article in Open medicine (Warsaw, Poland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The aim of this study is to construct a post-operative nomogram for renal pelvic cancer, thereby addressing a gap in the current academic literature and offering a valuable tool for predicting patient outcomes following surgical intervention. Methods: This study utilized data from the Surveillance, Epidemiology, and End Results program (2004-2017) to analyze patients diagnosed with renal pelvic cancer who underwent surgery. Variables analyzed included demographics, histology, grade, stage, and treatment modalities. Statistical analysis involved Kaplan-Meier and Cox models, developing a nomogram to predict 1-, 3-, and 5-year cancer-specific survival (CSS), validated through receiver operating characteristic (ROC) curves, calibration, and decision curve analysis (DCA) to assess clinical utility. Results: The training cohort consisted of 1,486 patients, and the validation cohort comprised 637 patients. Factors affecting CSS, analyzed through univariate and multivariate models, included age, histology, cancer grade, stage, and treatment modalities. The developed nomogram, tested via ROC curves and calibration plots, showed robust predictive accuracy for CSS across both cohorts, with its clinical utility demonstrated through DCA. Conclusion: Age, histology, grade, and stage were significant risk factors for CSS in renal pelvic urothelial carcinoma post-surgery. A nomogram utilizing these factors aids in evidence-based clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.